Cost considerations in the treatment of oropharyngeal squamous cell carcinoma

Eric J. Moore, Michael L. Hinni, Kerry D. Olsen, Daniel L. Price, Rebecca R. Laborde, Jared C. Inman

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives. To determine the cost of treatment of oropharyngeal squamous cell carcinoma (OP SCCA) with transoral surgery with concomitant neck dissection (TOS), TOS with adjuvant radiation therapy (TOS + RT), TOS with adjuvant chemoradiation therapy (TOS + CRT), and primary chemoradiation therapy (CRT).Study Design. Case series.Setting. Two tertiary care teaching hospitals.Subjects and Methods. Using the databases of 2 teaching hospitals, patients were identified who had OP SCCA treated with TOS, TOS + RT, TOS + CRT, and primary CRT in 2009 to 2010. Costs were analyzed from an institutional perspective looking at reimbursement. Patients with government payers and patients with private payers in each group were identified, and net revenue data obtained for the 3-month period from diagnosis were calculated and averaged for each group. Cost was defined as the reimbursement for all charges surrounding the 3-month episode of treatment. All revenue associated with inpatient and outpatient care, including pharmacy charges, was included.Results. The mean cost of TOS (private payers/government payers) was $37,435/$15,664 (range, $22,486-$48,746/$13,325-$16,885). The mean cost of TOS + RT (private payers/government payers) was $74,484/ $34,343 (range, $72,400-$84,825/$31,565-$40, 810). The mean cost of TOS + CRT (private payers/government payers) was $191,780/$53,245 (range, $145,450-$217,220/ $49,400-$58,325). The mean cost of CRT (private payers/government payers) was $198,285/$57,429 (range, $168,216-$298, 945/$52,900-$59,545).Conclusion. An algorithm of transoral surgical treatment of OP SCCA with adjuvant treatment as indicated by pathology is more cost conscious than an algorithm of treatment of all OP SCCA with CRT.

Original languageEnglish (US)
Pages (from-to)946-951
Number of pages6
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume146
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Squamous Cell Carcinoma
Costs and Cost Analysis
Therapeutics
Teaching Hospitals
Neck Dissection
Tertiary Healthcare
Ambulatory Care
Health Care Costs
Inpatients
Radiotherapy
Databases
Pathology

Keywords

  • cost
  • head and neck squamous cell carcinoma
  • oropharyngeal cancer

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Moore, E. J., Hinni, M. L., Olsen, K. D., Price, D. L., Laborde, R. R., & Inman, J. C. (2012). Cost considerations in the treatment of oropharyngeal squamous cell carcinoma. Otolaryngology - Head and Neck Surgery (United States), 146(6), 946-951. https://doi.org/10.1177/0194599812437534

Cost considerations in the treatment of oropharyngeal squamous cell carcinoma. / Moore, Eric J.; Hinni, Michael L.; Olsen, Kerry D.; Price, Daniel L.; Laborde, Rebecca R.; Inman, Jared C.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 146, No. 6, 06.2012, p. 946-951.

Research output: Contribution to journalArticle

Moore, Eric J. ; Hinni, Michael L. ; Olsen, Kerry D. ; Price, Daniel L. ; Laborde, Rebecca R. ; Inman, Jared C. / Cost considerations in the treatment of oropharyngeal squamous cell carcinoma. In: Otolaryngology - Head and Neck Surgery (United States). 2012 ; Vol. 146, No. 6. pp. 946-951.
@article{f4643dfe88db47f78f5abd4f55bff18f,
title = "Cost considerations in the treatment of oropharyngeal squamous cell carcinoma",
abstract = "Objectives. To determine the cost of treatment of oropharyngeal squamous cell carcinoma (OP SCCA) with transoral surgery with concomitant neck dissection (TOS), TOS with adjuvant radiation therapy (TOS + RT), TOS with adjuvant chemoradiation therapy (TOS + CRT), and primary chemoradiation therapy (CRT).Study Design. Case series.Setting. Two tertiary care teaching hospitals.Subjects and Methods. Using the databases of 2 teaching hospitals, patients were identified who had OP SCCA treated with TOS, TOS + RT, TOS + CRT, and primary CRT in 2009 to 2010. Costs were analyzed from an institutional perspective looking at reimbursement. Patients with government payers and patients with private payers in each group were identified, and net revenue data obtained for the 3-month period from diagnosis were calculated and averaged for each group. Cost was defined as the reimbursement for all charges surrounding the 3-month episode of treatment. All revenue associated with inpatient and outpatient care, including pharmacy charges, was included.Results. The mean cost of TOS (private payers/government payers) was $37,435/$15,664 (range, $22,486-$48,746/$13,325-$16,885). The mean cost of TOS + RT (private payers/government payers) was $74,484/ $34,343 (range, $72,400-$84,825/$31,565-$40, 810). The mean cost of TOS + CRT (private payers/government payers) was $191,780/$53,245 (range, $145,450-$217,220/ $49,400-$58,325). The mean cost of CRT (private payers/government payers) was $198,285/$57,429 (range, $168,216-$298, 945/$52,900-$59,545).Conclusion. An algorithm of transoral surgical treatment of OP SCCA with adjuvant treatment as indicated by pathology is more cost conscious than an algorithm of treatment of all OP SCCA with CRT.",
keywords = "cost, head and neck squamous cell carcinoma, oropharyngeal cancer",
author = "Moore, {Eric J.} and Hinni, {Michael L.} and Olsen, {Kerry D.} and Price, {Daniel L.} and Laborde, {Rebecca R.} and Inman, {Jared C.}",
year = "2012",
month = "6",
doi = "10.1177/0194599812437534",
language = "English (US)",
volume = "146",
pages = "946--951",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Cost considerations in the treatment of oropharyngeal squamous cell carcinoma

AU - Moore, Eric J.

AU - Hinni, Michael L.

AU - Olsen, Kerry D.

AU - Price, Daniel L.

AU - Laborde, Rebecca R.

AU - Inman, Jared C.

PY - 2012/6

Y1 - 2012/6

N2 - Objectives. To determine the cost of treatment of oropharyngeal squamous cell carcinoma (OP SCCA) with transoral surgery with concomitant neck dissection (TOS), TOS with adjuvant radiation therapy (TOS + RT), TOS with adjuvant chemoradiation therapy (TOS + CRT), and primary chemoradiation therapy (CRT).Study Design. Case series.Setting. Two tertiary care teaching hospitals.Subjects and Methods. Using the databases of 2 teaching hospitals, patients were identified who had OP SCCA treated with TOS, TOS + RT, TOS + CRT, and primary CRT in 2009 to 2010. Costs were analyzed from an institutional perspective looking at reimbursement. Patients with government payers and patients with private payers in each group were identified, and net revenue data obtained for the 3-month period from diagnosis were calculated and averaged for each group. Cost was defined as the reimbursement for all charges surrounding the 3-month episode of treatment. All revenue associated with inpatient and outpatient care, including pharmacy charges, was included.Results. The mean cost of TOS (private payers/government payers) was $37,435/$15,664 (range, $22,486-$48,746/$13,325-$16,885). The mean cost of TOS + RT (private payers/government payers) was $74,484/ $34,343 (range, $72,400-$84,825/$31,565-$40, 810). The mean cost of TOS + CRT (private payers/government payers) was $191,780/$53,245 (range, $145,450-$217,220/ $49,400-$58,325). The mean cost of CRT (private payers/government payers) was $198,285/$57,429 (range, $168,216-$298, 945/$52,900-$59,545).Conclusion. An algorithm of transoral surgical treatment of OP SCCA with adjuvant treatment as indicated by pathology is more cost conscious than an algorithm of treatment of all OP SCCA with CRT.

AB - Objectives. To determine the cost of treatment of oropharyngeal squamous cell carcinoma (OP SCCA) with transoral surgery with concomitant neck dissection (TOS), TOS with adjuvant radiation therapy (TOS + RT), TOS with adjuvant chemoradiation therapy (TOS + CRT), and primary chemoradiation therapy (CRT).Study Design. Case series.Setting. Two tertiary care teaching hospitals.Subjects and Methods. Using the databases of 2 teaching hospitals, patients were identified who had OP SCCA treated with TOS, TOS + RT, TOS + CRT, and primary CRT in 2009 to 2010. Costs were analyzed from an institutional perspective looking at reimbursement. Patients with government payers and patients with private payers in each group were identified, and net revenue data obtained for the 3-month period from diagnosis were calculated and averaged for each group. Cost was defined as the reimbursement for all charges surrounding the 3-month episode of treatment. All revenue associated with inpatient and outpatient care, including pharmacy charges, was included.Results. The mean cost of TOS (private payers/government payers) was $37,435/$15,664 (range, $22,486-$48,746/$13,325-$16,885). The mean cost of TOS + RT (private payers/government payers) was $74,484/ $34,343 (range, $72,400-$84,825/$31,565-$40, 810). The mean cost of TOS + CRT (private payers/government payers) was $191,780/$53,245 (range, $145,450-$217,220/ $49,400-$58,325). The mean cost of CRT (private payers/government payers) was $198,285/$57,429 (range, $168,216-$298, 945/$52,900-$59,545).Conclusion. An algorithm of transoral surgical treatment of OP SCCA with adjuvant treatment as indicated by pathology is more cost conscious than an algorithm of treatment of all OP SCCA with CRT.

KW - cost

KW - head and neck squamous cell carcinoma

KW - oropharyngeal cancer

UR - http://www.scopus.com/inward/record.url?scp=84864746118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864746118&partnerID=8YFLogxK

U2 - 10.1177/0194599812437534

DO - 10.1177/0194599812437534

M3 - Article

C2 - 22344182

AN - SCOPUS:84864746118

VL - 146

SP - 946

EP - 951

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 6

ER -